Foreign drug firms deny wrongdoing as Indian ministry points to trials 'deficiencies'
This article was originally published in SRA
Executive Summary
In an ongoing legal case concerning clinical trials in India, the health ministry told the court ofpast lapses committed by foreign companies, including Pfizer, Sanofi and the contract services Quintiles, in studies conducted at the Bhopal Memorial Hospital and Research Centre. The firms involved have strongly denied any wrongdoing.
You may also be interested in...
How Heads Of Indian Firms Rallied To Sustain Global Supplies Amid COVID-19
The leadership of top Indian firms recounted at the IPA Forum how they got together on a joint 45-minute call daily in the early phase of the pandemic to collaborate and ensure uninterrupted supplies of medicines both in India and globally. The executives also shared views on telemedicine and digitalization trends at the event.
SARS-CoV-2 Variants And Current Vaccines: “It’s Not All Or Nothing”
Experts including renowned virologist Peter Piot, FDA’s Peter Marks and CEPI’s Richard Hatchett discussed multiple dimensions pertaining to coronavirus variants and existing vaccines at a recent conference, noting enhanced post-deployment surveillance is underway in the US. While there’s no need to panic for every variant that emerges, equitable access to vaccines is critical to ensure that gains made over last year are not undone, they said.
Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: